Scarica l'app Stockscreener
4.13
12.53%
0.46
Dopo l'orario di chiusura:
4.10
-0.03
-0.73%
Precedente Chiudi:
$3.67
Aprire:
$3.69
Volume 24 ore:
449.21K
Relative Volume:
0.64
Capitalizzazione di mercato:
$137.10M
Reddito:
-
Utile/perdita netta:
$-86.60M
Rapporto P/E:
-1.4581
EPS:
-2.8324
Flusso di cassa netto:
$-67.37M
1 W Prestazione:
-0.48%
1M Prestazione:
-1.43%
6M Prestazione:
-25.99%
1 anno Prestazione:
-64.97%
Intervallo 1D:
$3.60
$4.14
Intervallo di 1 settimana:
$3.60
$4.2664
Portata 52W:
$1.45
$13.63
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Confronta LXEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.13 | 198.11M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-06 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-28 | Iniziato | Chardan Capital Markets | Buy |
| 2023-11-28 | Iniziato | JP Morgan | Overweight |
| 2023-11-28 | Iniziato | Leerink Partners | Outperform |
| 2023-11-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Lexeo Therapeutics Inc. Stock Analysis and ForecastUnstoppable profit momentum - Autocar Professional
Is Lexeo Therapeutics Inc. a good long term investmentExtraordinary profit generation - Autocar Professional
What risks could impact Lexeo Therapeutics Inc. stock performanceDynamic investment growth - jammulinksnews.com
What drives Lexeo Therapeutics Inc. stock priceFree Stock Market Return Analysis - Autocar Professional
What analysts say about Lexeo Therapeutics Inc. stockFree Daily Trading Room Entry - Autocar Professional
Will Lexeo Therapeutics Inc. stock split in the near futureSafe and Smart Investment Picks - beatles.ru
Lexeo Therapeutics (NASDAQ:LXEO) & Organogenesis (NASDAQ:ORGO) Head to Head Analysis - Defense World
What analysts say about Lexeo Therapeutics Inc. stock outlookFree Investment Portfolio Suggestions - Newser
How high can Lexeo Therapeutics Inc. stock price go in 2025Safe and Smart Investment Picks - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru
Why Lexeo Therapeutics Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
How Lexeo Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Lexeo Therapeutics soars 96% following March Fair Value signal By Investing.com - Investing.com South Africa
Lexeo Therapeutics soars 96% following March Fair Value signal - Investing.com
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target - Investing.com Nigeria
Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target By Investing.com - Investing.com South Africa
Lexeo Therapeutics stock rises after FDA breakthrough designation By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Secures FDA Breakthrough Therapy Designation for LX2006, Shares Rise 8% in Pre-market Trade. - AInvest
Lexeo Therapeutics announces FDA Breakthrough Therapy Designation for LX2006 - TipRanks
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - Nasdaq
FDA grants breakthrough therapy designation to Lexeo’s FA treatment - Investing.com
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewswire
FDA Breakthrough: Lexeo's Gene Therapy Shows Promise in Fatal Rare Disease Treatment - Stock Titan
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan | ATNFW SEC FilingForm 8-K - Stock Titan
LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan - Stock Titan
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):